Get notified when NVCT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (new) — The company acknowledges that testing could reveal material weaknesses in internal controls over financial reporting, a risk to financial reporting reliability.
- License Agreement Financing Condition (new) — The company must raise $50 million within six months or risk losing the license to NXP100 and NXP200, which could materially harm its pipeline.
- Insider Ownership Concentration (new) — Insiders control about 40% of voting stock, giving them significant influence over corporate decisions and potentially deterring takeovers.
Nuvectis Pharma prices $100M primary offering of 5M shares at $20.00 each
Filed June 30, 2026 · ~2 min read
Key Changes
-
high
Nuvectis Pharma is selling 5,000,000 new shares at $20.00 per share, raising $100M gross for the company; underwriters have a 30-day option for 750,000 more shares.
The Offering verify on EDGAR → -
high
Net proceeds to the company are estimated at $93M (or $107M if the underwriters' option is fully exercised), after underwriting discounts and commissions.
Use of Proceeds verify on EDGAR → -
high
Proceeds will fund development of NXP100, NXP200, and NXP900, plus hiring, capital expenditures, and general corporate purposes; no specific allocation is given.
Use of Proceeds verify on EDGAR →
5 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (GIS 10-Q) is open in full — no account needed.
Partner
Trade NVCT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify